PAPER Confettura AD, Cuboni E, Ammar MR, Jia S, Gomes GM, Yuanxiang P, Raman R, Li T, Grochowska KM, Ahrends R, Karpova A, Dityatev A, Kreutz MR

Neddylation-dependent protein degradation is a nexus between synaptic insulin resistance, neuroinflammation and Alzheimer's disease.

Transl Neurodegener. 2022 Jan 6;11(1):2. PubMed.

PAPER Verma M, Lizama BN, Chu CT

Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration.

Transl Neurodegener. 2022 Jan 25;11(1):3. PubMed.

PAPER Gao L, Zhang Y, Sterling K, Song W

Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential.

Transl Neurodegener. 2022 Jan 28;11(1):4. PubMed.

PAPER Pang SY, Lo RC, Ho PW, Liu HF, Chang EE, Leung CT, Malki Y, Choi ZY, Wong WY, Kung MH, Ramsden DB, Ho SL

LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.

Transl Neurodegener. 2022 Jan 31;11(1):5. PubMed.

PAPER Martinez-Valbuena I, Visanji NP, Kim A, Lau HH, So RW, Alshimemeri S, Gao A, Seidman MA, Luquin MR, Watts JC, Lang AE, Kovacs GG

Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy.

Transl Neurodegener. 2022 Feb 7;11(1):7. PubMed.

PAPER Devos H, Gustafson K, Liao K, Ahmadnezhad P, Estes B, Martin LE, Mahnken JD, Brooks WM, Burns JM

EEG/ERP evidence of possible hyperexcitability in older adults with elevated beta-amyloid.

Transl Neurodegener. 2022 Feb 9;11(1):8. PubMed.

PAPER Jakova E, Moutaoufik MT, Lee JS, Babu M, Cayabyab FS

Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.

Transl Neurodegener. 2022 Feb 10;11(1):9. PubMed.

PAPER Chang EE, Ho PW, Liu HF, Pang SY, Leung CT, Malki Y, Choi ZY, Ramsden DB, Ho SL

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.

Transl Neurodegener. 2022 Feb 14;11(1):10. PubMed.

PAPER Mahlknecht P, Marini K, Werkmann M, Poewe W, Seppi K

Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Transl Neurodegener. 2022 Feb 21;11(1):11. PubMed.

PAPER Halim D, Gao FB

RNA targets of TDP-43: Which one is more important in neurodegeneration?

Transl Neurodegener. 2022 Feb 25;11(1):12. PubMed.

PAPER Lv YQ, Yuan L, Sun Y, Dou HW, Su JH, Hou ZP, Li JY, Li W

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model.

Transl Neurodegener. 2022 Mar 7;11(1):14. PubMed.

PAPER Isonaka R, Sullivan P, Goldstein DS

Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study.

Transl Neurodegener. 2022 Mar 8;11(1):15. PubMed.

PAPER Kim D, Kim S, Sung A, Patel N, Wong N, Conboy MJ, Conboy IM

Autologous treatment for ALS with implication for broad neuroprotection.

Transl Neurodegener. 2022 Mar 11;11(1):16. PubMed.

PAPER Zamani A, Walker AK, Rollo B, Ayers KL, Farah R, O'Brien TJ, Wright DK

Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis.

Transl Neurodegener. 2022 Mar 15;11(1):17. PubMed.

PAPER Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H

Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.

Transl Neurodegener. 2022 Mar 18;11(1):18. PubMed.